Literature DB >> 29609223

Utility of community-acquired pneumonia severity scores in guiding disposition from the emergency department: Intensive care or short-stay unit?

Julian M Williams1,2, Jaimi H Greenslade1,2, Kevin H Chu1,2, Anthony Ft Brown1,2, Jeffrey Lipman2,3.   

Abstract

OBJECTIVE: To assess community-acquired pneumonia severity scores from two perspectives: (i) prediction of ICU admission or mortality; and (ii) utility of low scores for prediction of discharge within 48 h, potentially indicating suitability for short-stay unit admission.
METHODS: Patients with community-acquired pneumonia were identified from a prospective database of emergency patients admitted with infection. Pneumonia severity index (PSI), CURB-65, CORB, CURXO, SMARTCOP scores and the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) minor criteria were calculated. Diagnostic accuracy statistics (sensitivity, specificity, predictive values, likelihood ratios and area under receiver operating characteristic curves [AUROC]) were determined for both end-points.
RESULTS: Of 618 patients admitted with community-acquired pneumonia judged eligible for invasive therapies, 75 (12.1%) were admitted to ICU or deceased at 30 days, and 87 (14.1%) were discharged within 48 h. All scores effectively stratified patients into categories of risk. For prediction of severe pneumonia, SMARTCOP, CURXO and IDSA/ATS discriminated well (AUROC 0.84-0.87). SMARTCOP and CURXO showed optimal sensitivity (85% [95% confidence interval (CI) 75-92]), while specificity was highest for CORB and CURB-65 (93% and 94%, respectively). Using lowest risk categories for prediction of discharge within 48 h, only SMARTCOP and CURXO showed specificity >80%. PSI demonstrated highest positive predictive value (31% [95% CI 24-39]) and AUROC (0.74 [95% CI 0.69-0.79]).
CONCLUSIONS: Community-acquired pneumonia severity scores had different strengths; SMARTCOP and CURXO were sensitive with potential to rule out severe disease, while the high specificity of CORB and CURB-65 facilitated identification of patients at high risk of requirement for ICU. Low severity scores were not useful to identify patients suitable for admission to short-stay units.
© 2018 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine.

Entities:  

Keywords:  clinical decision-making; emergency medicine; pneumonia; prognosis

Mesh:

Year:  2018        PMID: 29609223     DOI: 10.1111/1742-6723.12947

Source DB:  PubMed          Journal:  Emerg Med Australas        ISSN: 1742-6723            Impact factor:   2.151


  4 in total

1.  Performance of the CORB (Confusion, Oxygenation, Respiratory Rate, and Blood Pressure) Scale for the Prediction of Clinical Outcomes in Pneumonia.

Authors:  Luis F Reyes; Alirio R Bastidas; Eduardo Tuta Quintero; Juan S Frías; Álvaro F Aguilar; Karen D Pedreros; Manuela Herrera; Laura D Saza; Alejandra P Nonzoque; Laura E Bello; Maria D Hernández; Germán A Carmona; Anyelinne Jaimes; Silvia M Ramírez; Natalia Murillo
Journal:  Can Respir J       Date:  2022-06-03       Impact factor: 2.130

Review 2.  The Use of the SMART-COP Score in Predicting Severity Outcomes Among Patients With Community-Acquired Pneumonia: A Meta-Analysis.

Authors:  Rahat A Memon; Muhammad Affan Rashid; Sahithi Avva; Venkata Anirudh Chunchu; Huda Ijaz; Zubair Ahmad Ganaie; Albeena Kabir Dar; Neelum Ali
Journal:  Cureus       Date:  2022-07-25

3.  Derivation and Validation of a Novel Severity Scoring System for Pneumonia at Intensive Care Unit Admission.

Authors:  Thomas A Carmo; Isabella B Ferreira; Rodrigo C Menezes; Gabriel P Telles; Matheus L Otero; Maria B Arriaga; Kiyoshi F Fukutani; Licurgo P Neto; Sydney Agareno; Nivaldo M Filgueiras Filho; Bruno B Andrade; Kevan M Akrami
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

4.  Assess COVID-19 prognosis … but be aware of your instrument's accuracy!

Authors:  Maurizia Capuzzo; Andre Carlos Kajdacsy-Balla Amaral; Vincent X Liu
Journal:  Intensive Care Med       Date:  2021-10-05       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.